Luteinizing hormone response to controlled-release deslorelin in estradiol benzoate primed ovariectomized gilts.
Development of a controlled release formulation of gonadotropin releasing hormone that would stimulate a LH surge capable of reducing the time span of ovulations would greatly benefit reproductive management because a single timed insemination could be used. A dose-response study was conducted to determine if Deslorelin, a potent gonadotropin releasing hormone analogue, delivered via the SABER system, a biodegradable controlled release system, would stimulate an ovulatory-like LH surge in the pig. Twenty ovariectomized gilts, approximately 200 d old and 100 kg body weight (BW), received estradiol benzoate (15 microg/kg BW im) and 48 h later, the gilts were given deslorelin at 0, 12.5, 25.0, 50.0 or 100.0 microg im (n = 4 each treatment group). Compared to controls, mean blood deslorelin concentrations were still elevated at 30 h after deslorelin. Mean deslorelin magnitude, area under the curve and duration were sequentially greater (P<0.05) in a dose-dependent sequence. Compared to controls, serum LH concentrations were elevated (P<0.05) for 6 to 12 h after deslorelin. A dose-response relationship was absent for all parameters of LH secretion. Magnitude of the serum LH response was greatest (P<0.05) in the 12.5 microg and 50.0 microg groups, whereas area under the curve was lower (P<0.05) after 25.0 microg of deslorelin than after 12.5, 50.0 and 100.0 microg, which were not different from each other. Thus, no more than 12.5 microg of deslorelin is necessary to obtain maximum LH release in the model studied and doses less than 12.5 microg may also be effective.
Kraeling
R R
RR
Richard B. Russell Agricultural Research Center, ARS, USDA, Athens, GA 30604, USA. rkraelin@ars.usda.gov
Barb
C R
CR
Rampacek
G B
GB
Thompson
D L
DL
Gibson
J W
JW
Sullivan
S A
SA
Simon
B
B
Burns
P J
PJ
D000818:Animals; D019540:Area Under Curve; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D004958:Estradiol / Q000008:administration & dosage; D004973:Estrus Synchronization / Q000187:drug effects / Q000502:physiology*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000097:blood / Q000502:physiology*; D010052:Ovariectomy / Q000662:veterinary; D011863:Radioimmunoassay / Q000662:veterinary; D013552:Swine / Q000502:physiology*; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives
D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; C066438:deslorelin